Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
A work-stretched US FDA has several key approval application still to review by the end of 2023.
Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.